1. Generics Bulletin
  2. >>Podcasts

The Generics Bulletin Podcast: Stelara Biosimilar Launches In The US

Editors Discuss The Latest Developments For Ustekinumab Rivals

 
• By Dave Wallace

In the wake of multiple ustekinumab biosimilar rivals to Stelara launching in the US at the end of February, Generics Bulletin’s editors discuss the market dynamics and the latest key developments.

Generic Bulletin Podcast

This edition of the Generics Bulletin podcast sees executive editor Dave Wallace and deputy editor Dean Rudge discuss the latest developments around Stelara (ustekinumab) biosimilars in the US.

Last year, Generics Bulletin looked ahead to the imminent US onset of biosimilar competition to Stelara to ask whether it would be “groundhog day” for the industry after experiences with Humira (adalimumab) biosimilars in 2023.

At the end of 2024, we took a look at the approved contenders that were set to enter the market, before in January and February reporting on the biosimilar launches and their price discounts – as well as bringing news of a legal challenge from J&J threatening to block Sandoz’s private-label ustekinumab biosimilar.

More from Podcasts

The Generics Bulletin Podcast: Stelara Biosimilar Launches In The US

 
• By Dave Wallace

In the wake of multiple ustekinumab biosimilar rivals to Stelara launching in the US at the end of February, Generics Bulletin’s editors discuss the market dynamics and the latest key developments.

The Generics Bulletin Podcast: Highlights Of 2024

 
• By Dave Wallace

Generics Bulletin's editorial team discusses key topics from the year, including the latest rankings of the Generics Bulletin Top 50, Amgen’s surprise launch of a US Eylea biosimilar, the EU’s Urban Waste Water Treatment Directive and supply-chain issues for the off-patent sector.

More from Business

Alvotech And Advanz Make First Omalizumab Filing

 
• By Dave Wallace

Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).

Hyloris Closes A Dramatic 2024 With A Move Towards Profit

 
• By Adam Zamecnik

After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.

Cipla Becomes Formosa’s Latest Clobetasol Partner With 11-Country Deal

 
• By Dean Rudge

Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.